Silence Therapeutics plc

Ionis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

Cytokinetics Brought Down In the earlier halcyon days of biotech, the licensing of a biotech company’s lead drug to a big pharma partner would be associated with a substantial jump in the licensor’s

The Jefferies London Healthcare Conference is now in its 15th year, and is firmly established as Europe’s biggest biopharma investment meeting. Here are some key themes to watch out for at the event,